ahlam1399
09-23-2016, 01:52 PM
BRIEF-GSK files regulatory submissions in U.S. and Europe for lupus drug
* GSK an**unces regulatory submissions for subcutaneousformulation of Benlysta (Belimumab) for patients with systemiclupus diseasehttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=poQBL3-5o34:DeHGptmkxRk:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=poQBL3-5o34:DeHGptmkxRk:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=poQBL3-5o34:DeHGptmkxRk:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=poQBL3-5o34:DeHGptmkxRk:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=poQBL3-5o34:DeHGptmkxRk:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/poQBL3-5o34
* GSK an**unces regulatory submissions for subcutaneousformulation of Benlysta (Belimumab) for patients with systemiclupus diseasehttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=poQBL3-5o34:DeHGptmkxRk:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=poQBL3-5o34:DeHGptmkxRk:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=poQBL3-5o34:DeHGptmkxRk:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=poQBL3-5o34:DeHGptmkxRk:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=poQBL3-5o34:DeHGptmkxRk:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/poQBL3-5o34